- cafead Aug 25, 2023 at 12:02: PM
via Just a few short weeks after Wegovy posted a major cardio outcomes win, Novo Nordisk has chalked up another heart-related victory for its semaglutide star.
In the phase 3 study STEP HFpEF, semaglutide 2.4 mg (Wegovy’s dose) bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction (HFpEF).
article source
In the phase 3 study STEP HFpEF, semaglutide 2.4 mg (Wegovy’s dose) bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction (HFpEF).
article source